Welcome Guest | Register / Login

Pharmaceuticals Market Research Reports

The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this i... View more

Sort By
Title Published Price Buy Now
Belgium Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: With structurally higher prices than many regional markets and quickly rising pharmaceutical consumption, Belgium will continue to present a high level of potential reward to drugmaker. Notably, a distinct lack of price transpar...
Jun 2015 $ 1295
Indonesia Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Indonesia's healthcare expenditure will grow robustly. Key to this trajectory is rising household incomes which will have strong positive ramifications due to the dominant role of private spending as a source of healthcare finan...
Jun 2015 $ 1295
Namibia Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Pharmaceuticals originating from neighbouring South Africa dominate the domestic market, with Indian firms also having a strong presence. The market is mostly comprised of generic medicines, though patented drugmakers do supply ...
Jun 2015 $ 1295
Qatar Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Qatar's Annual Health Report for 2014 confirms our view that the healthcare sector will experience strong growth over our forecast period. Sizeable expansion projects are underway, health insurance coverage is increasing and gov...
Jun 2015 $ 1295
Serbia Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: A focus on reining in Serbia's bloated public sector following an agreement with the IMF will inevitably lead to cuts in healthcare spending. Furthermore, Serbia's healthcare authorities will continue to cut prices to reduce the...
Jun 2015 $ 1295
Spain Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Spain's non-transparent and unpredictable government medicine pricing system and the implementation of numerous emergency measures to contain pharmaceutical spending will highly disrupt multinational drugmakers' strategy and rev...
Jun 2015 $ 1295
Sri Lanka Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Domestic generic drugmakers will be at a distinct advantage under Sri Lanka's proposed national medicinal policy. With directives boosting generic drug sales through generic substitution, local pharmaceutical companies will be f...
Jun 2015 $ 1295
China Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Multinational pharmaceutical companies will continue to invest and grow their presence in China, despite the slowdown in the economy. Driving this outlook is the outperformance of the pharmaceutical sector as authorities continu...
Jun 2015 $ 1295
Bangladesh Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Bangladesh's pharmaceutical and healthcare sector growth will continue to stand on robust long-term fundamentals, including population growth, rising incomes, urbanisation and economic expansion. Moreover, the country's efforts ...
Jun 2015 $ 1295
Cuba Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: A new focus on the improvement of global trade ties along with economic liberalisation, albeit slow, will ensure Cuba's healthcare and pharmaceutical markets continue their positive growth trajectory over the long-term. Initial ...
Jun 2015 $ 1295
Finland Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Finland's growing and ageing population will drive pharmaceutical demand. Despite being relatively small in size compared to some of its Western European counterparts, the market is boosted by high GDP per-capita, ensuring conti...
Jun 2015 $ 1295
Iran Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: The gradual easing of sanctions in Iran will lead to an uptick in interest from multinational pharmaceutical companies, many of which chose not to do business in Iran during this time. The supply of high value patented medicines...
Jun 2015 $ 1295
Ireland Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: In line with our long-standing view, merger and acquisition activity targeting Irish pharmaceutical firms has remained intense in H115, while this trend is expected to continue over a multiquarter horizon against a backdrop of s...
Jun 2015 $ 1295
Israel Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Drug price cuts and the addition of new pharmaceuticals to the national drug formulary demonstrate the government's commitment to expanding access to healthcare. Healthcare spending will remain elevated despite the fiscal defici...
Jun 2015 $ 1295
Italy Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Drugmakers will continue to face revenue earning challenges in Italy. In 2014, spending by Italy's national healthcare service, Servizio Sanitario Nazionale (SSN), fell for the seventh consecutive year in which SSN spending on d...
Jun 2015 $ 1295
Moldova Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Moldova is heavily dependent on the success of outside sources, such as the European and Russian economy. In this regard, Moldova's economy is continuing to suffer greatly from the declining euro vs the US dollar and GBP combine...
Jun 2015 $ 1295
Morocco Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Similar to other North African markets, Morocco's inclusion on PhRMA's Special 301 Submission for 2015 for intellectual property and pricing issues highlights the ongoing challenges that multinational drugmakers face in the mark...
Jun 2015 $ 1295
Philippines Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Innovative pharmaceutical companies will continue to face a challenging business environment in the Philippines. Many concerns limiting the sales of patented drugs in the country remain unaddressed, including the low levels of i...
Jun 2015 $ 1295
Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Over the forthcoming years, growth in Saudi Arabia's pharmaceutical market will remain elevated. The government's commitment to the sector and health insurance expansion will be key drivers of sector growth, with the risks from ...
Jun 2015 $ 1295
Slovakia Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Eurozone recovery and an improving domestic economic outlook will provide a boost to healthcare expenditure in Slovakia in the short-term. Over the longer term, we expect healthcare spending to accelerate given Slovakia's ageing...
Jun 2015 $ 1295
Zimbabwe Pharmaceuticals and Healthcare Report Q3 2015
By Business Monitor International
BMI View: Our outlook of modest growth for Zimbabwe's pharmaceutical sector should be treated with caution as poor monitoring and recording practices along with the country's reliance on aid from various sources make market figures unreli...
Jun 2015 $ 1295
Research on China Anesthetic Industry , 2015
By Chisult Insight
With the increasing numbers of domestic surgeries, the market size of Chinese anesthetic also increased a lot. The market size of Chinese anesthetic industry reached nearly RMB 6400 million in 2014, increased by 18.8% from a YoY base. Among which,...
Jun 2015 $ 1000
Desvenlafaxine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)
By Ark Patent Intelligence
Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot save...
Jun 2015 $ 600
Lorcaserin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)
By Ark Patent Intelligence
Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot save...
Jun 2015 $ 600
Riluzole - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)
By Ark Patent Intelligence
Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot save...
Jun 2015 $ 600